This is the authors' abstract. We don't add key points for this paper.
Background Natural killer cell engager (NKCE) has gained attention recently. Conventional NKCEs exhibit mild anti-tumor efficacy despite acceptable safety profiles. Therefore, next-generation NKCE development is essential to enhance efficacy. IL-15, a key NK cell activator, is explored in NKCE design. However, wild-type IL-15 shows significant toxicity in clinical trials. In this study, we present the development of a novel tetravalent NKCE platform (IL15v-NKCE) by incorporating a potency-reduced IL-15 element (IL15v) into our proprietary anti-NKp46 based NKCEs. Methods The activity of the IL15v moiety was assessed by quantifying pSTAT5 induction in primary immune cells and evaluating STAT5 activation in an IL-15 reporter cell line. The in vitro activity of IL15v-NKCE was determined using co-culture assays with NK and tumor cells. The in vivo anti-tumor efficacy and safety profile of IL15v-NKCE were evaluated in tumor-bearing mouse models. Results In vitro, IL15v selectively activates NK cells without affecting T cells, enhances NKCE cytotoxicity, prevents NK apoptosis, and promotes NK proliferation. In vivo, IL15v-NKCE shows good tolerability and superior anti-tumor efficacy compared to conventional NKCE. All four components (anti-NKp46, Fc, IL15v, anti–tumor-associated antigen) of IL15v-NKCE are essential for maximal activity, and IL15v-NKCE is more potent than the conventional NKCE when combined with anti-PD-1 in preclinical models. Conclusions By integrating IL15v into our anti-NKp46 based NKCEs, IL15v-NKCE has exhibited enhanced anti-tumor efficacy while maintaining an acceptable safety profile, thereby positioning it as a promising next-generation therapeutic modality for NK cell-based therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: